Market Place
Sourcing Support
Agenus Enters 3 New Clinical Collaborations
31 May 2022 //
CONTRACTPHARMA
Targovax ASA, Agenus collaborate on mutant KRAS cancer vaccine adjuvanted
07 Mar 2022 //
GLOBENEWSWIRE
Targovax granted Patents for ONCOS-102 + chemotherapy in China and Japan
17 Jan 2022 //
EURONEXT
Innovation Norway awards NOK 8.2 mn grant to Targovax for RAS vaccine
14 Jan 2022 //
PHARMABIZ
Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
20 Oct 2021 //
PRNEWSWIRE
Targovax Appoints Ola Melin as Head of Manufacturing
30 Sep 2021 //
CONTRACTPHARMA
Targovax gets EU patent for ONCOS-102 + chemotherapy in pleural mesothelioma
27 Sep 2021 //
PHARMABIZ
Targovax to present at upcoming scientific conferences
16 Aug 2021 //
PR NEWSWIRE
Lilly`s lebrikizumab improved skin clearance and itch in atopic dermatitis
15 Aug 2021 //
PR NEWSWIRE
US FDA grants fast track status to Targovax ONCOS-102
23 Jun 2021 //
PHARMABIZ
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102
17 Jun 2021 //
PRNEWSWIRE
Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
14 Jun 2021 //
PRNEWSWIRE
Targovax`s ONCOS-102 mesothelioma 24-month data shows median overall survival
10 Jun 2021 //
PRNEWSWIRE
Targovax announces clinical data from phase I/II clinical trials of ONCOS-102
25 Feb 2021 //
PHARMBIZ
Targovax announces clinical data from phase I/II clinical trials of ONCOS-102
24 Feb 2021 //
PHARMABIZ
Continued survival benefit in Targovax`s ONCOS-102 trial in at the 21
23 Feb 2021 //
PRNEWSWIRE
Continued survival benefit in Targovax`s ONCOS-102 trial mesothelioma at the 21
22 Feb 2021 //
PRNEWSWIRE
Targovax receives Fast-Track designation for ONCOS-102
15 Feb 2021 //
BIOSPACE
Targovax grants IOVaxis 3 extension to the exclusive license for TG mutant RAS
06 Jan 2021 //
PRNEWSWIRE
Targovax grants IOVaxis 3 months extension to the exclusive license option
06 Jan 2021 //
PRNEWSWIRE
Targovax announces impressive objective responses as well as effects
02 Dec 2020 //
PRNEWSWIRE
TARGOVAX ANNOUNCES IMPRESSIVE OBJECTIVE RESPONSES AS WELL AS EFFECT
01 Dec 2020 //
SCIENCE DAILY
Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma
24 Nov 2020 //
PRNEWSWIRE
Targovax announces that the ONCOS-102 and durvalumab trial successfully part 1
13 Oct 2020 //
PRNEWSWIRE
Targovax announces that the ONCOS-102 and durvalumab trial successfully
12 Oct 2020 //
PRNEWSWIRE
Targovax announces that the ONCOS-102 and durvalumab trial successfully part1
12 Oct 2020 //
PRNEWSWIRE
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor
04 Jun 2020 //
PRNEWSWIRE
Targovax Announces That Abstract on Interim Phase I Clinical Data
06 May 2020 //
PRNEWSWIRE
Targovax Announces That Abstract on Interim PhI Clinical Data From the Ph I/II
05 May 2020 //
PR NEWSWIRE
Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102
04 May 2020 //
PRNEWSWIRE
Targovax nabs Roche veteran as CSO
30 Apr 2020 //
FIERCE BIOTECH
Targovax & Valo Therapeutics Enter Collab to Develop RAS Neoantigen Coating
22 Apr 2020 //
PR NEWSWIRE
Targovax & Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen
21 Apr 2020 //
PR NEWSWIRE
Targovax Announces Completed Enrollment in the ONCOS-102 Trial
03 Mar 2020 //
PR NEWSWIRE
